EMEA-001665-PIP02-17

Key facts

Active substance
Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human βA-T87Q-globin gene
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0234/2019
PIP number
EMEA-001665-PIP02-17
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment of sickle cell disease
Route(s) of administration
Intravenous use
Contact for public enquiries
bluebird bio France 

Tel. +1 617 803 0296
E-mail: mgovignon@bluebirdbio.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating